Most stem-cell treatments have no acute complications. Most is not all.
Some IV patients experience mild flu-like symptoms the evening of treatment, usually resolving overnight. Direct-injection patients can expect soreness for several days. Rest settles it. Serious adverse events are rare and well-characterised.
See the side effects by frequencyAdverse events in MSC therapy occupy a clear spectrum: predictable mild reactions in a small minority, expected procedural soreness for direct-injection patients, and rare serious events that are well-characterised in the published literature. The chart below puts them side by side.
The honest framing: the most common adverse event is mild flu-like symptoms the evening of treatment, in a subset of patients. The rest is rare. None of it catches the program unprepared.
A subset of IV patients experience a mild flu-like syndrome the evening of treatment. The symptoms are typical: low-grade fever, mild body aches, some fatigue, occasionally a slight headache. They begin a few hours after the infusion and typically resolve overnight. A low-grade temperature is normal in the first 72 hours.
These symptoms are mild and self-limited. Patients are monitored throughout the infusion, simple over-the-counter support is available if a patient wants it, and your patient coordinator or your aftercare specialist is the person to call that evening or the next morning if anything worries you. Call if a fever lasts more than 24 hours.
Patients receiving direct injections (into a knee, hip, shoulder, hand, foot joint, or a spinal or disc compartment) can expect a different post-treatment experience. We inject the tendons, ligaments, and muscle that support the joint, not only the space inside it, so soreness and some swelling are common. They settle when the joint is rested and not overused for the first 7 to 10 days. Swelling or pain that is out of proportion, or keeps climbing, is a call to us.
Rest is what settles the first days. NSAIDs are held for at least 2 weeks after treatment. Some patients report a first change in a joint between weeks 4 and 12.
Patients with soreness substantially outside this window: more severe than expected, lasting longer than two weeks, or accompanied by signs of infection, are flagged for medical review. The team distinguishes between expected post-procedural inflammation and signs of an actual complication.
Across the published clinical literature and the operational experience of established programs, the categories of rare adverse events are well-characterised. Each has a known response. Serious events are rare across the published MSC literature. Not zero.
Hypersensitivity · Rate: very rare · published MSC literature
Patients can react to the cells or residual manufacturing components. Reactions during IV infusion are very rare in cord-derived MSC literature, but not zero.
Protocol response Continuous monitoring during infusion. Pause / stop on first sign. Antihistamines, corticosteroids, emergency support in the building.
Procedural · Rate: uncommon · spinal injections most often
Brief lightheadedness, nausea, or drop in blood pressure during or immediately after a direct injection. Most resolve within minutes with positioning.
Protocol response Trendelenburg positioning, IV fluids, monitoring. Patient released only after vitals stable.
Procedural · Rate: very low · sterile technique + cGMP
Any procedure that breaks skin carries some infection risk. Mitigated by sterile technique in the suite and cGMP standards in the cell preparation.
Protocol response Patient counselled on warning signs (escalating pain, redness or heat at the site after the first 24 hours, a fever that lasts more than 24 hours). You call your patient coordinator or your aftercare specialist.
Concurrent · Rate: rare · may be unrelated to therapy
A cardiac event, stroke, or other acute medical issue while in the treatment chair may or may not be related to the therapy. The response matters more than the cause.
Protocol response Hospital-based escalation. Same building, same chart, ICU in the same building. Not a 911 call.
QC failure (elsewhere) · Rate: preventable · upstream QC
If a clinic delivers cells that are largely non-viable, dead cells trigger a pro-inflammatory response rather than the anti-inflammatory effect intended.
Protocol response Day-of viability testing (see counts, viability, and dose). Below-threshold vials are not administered.
Vascular · Rate: rare · reported after IV infusions
Published reports describe clots after IV cell infusions. The risk is small, and it is mostly an IV risk.
Protocol response Gentle movement after treatment: walking after an IV, careful use of a treated joint. A swollen, painful calf is a call the same day. Sudden shortness of breath is emergency care first, then us.
Late · Rate: rare · documented in published literature
Symptoms emerging days or weeks after treatment require local evaluation. Continuity of records across borders is part of the protocol.
Protocol response Clinical record provided, certificate of analysis on request. Physician-to-physician consultation with US providers if needed.
A Serious Adverse Event (SAE) is any medical event during or after treatment that results in hospitalisation, prolongs an existing stay, causes lasting harm, or threatens life. Programs that say "we've never had a problem" without being able to describe what would happen if they did aren't the same as programs with a real SAE infrastructure.
Each phase is owned, documented, and handed off cleanly to the next. Press play to walk through, or click any phase.
1 / 5
Any acute event during the treatment session is managed in real time by the attending physician and the hospital's medical resources. The patient is moved to the appropriate level of care within the hospital if needed, with continuity of clinical team and continuity of records.
Patients are observed for a defined period after treatment before discharge. Vitals, symptom report, and a physician check confirm the patient is stable for return travel. Any concern delays discharge and may convert the visit into an overnight observation stay.
Most patients are home the same day, with an overnight only when intake says so. Your patient coordinator or your aftercare specialist is the person to call that evening or the next morning, and a physician joins when needed. For patients with mild flu-like symptoms, this is where they're confirmed and reassurance is provided.
If a serious event occurs after return, the patient is directed to local emergency care, with Celva providing whatever documentation US providers need to assess the case: the certificate of analysis on request, the clinical record from the visit, the contact information for the treating physicians for direct consultation.
Every SAE is documented, reviewed by the clinical team, and incorporated into protocol refinement where applicable. The structured documentation is what lets the program answer a question about safety from a record rather than a guess.
The risk profile of MSC therapy from a properly run program is favourable. The literature, across thousands of patients and years of follow-up, consistently shows MSC therapy as well-tolerated. Adverse events occur. Most are mild and self-limited. Serious events are rare and, in a hospital-based program, manageable.
The patient decision isn't whether MSC therapy is risky. It's which program is doing the work to manage the risk that does exist.
A question worth asking any clinic
"Walk me through what happens if I have a reaction during the infusion, minute by minute, room by room."
The acceptable answer names the team and the unit. An evasive answer or one that ends with "we call 911" is your answer.
0 / 5 noted
This page exists because patients deserve a candid conversation about what can go wrong and how the program is structured to handle it. Most clinic websites avoid this topic. The avoidance is itself a signal: a program that has thought carefully about safety doesn't need to bury the question. It needs to answer it.
The protocol that makes those statements durable is the SAE infrastructure: hospital-based treatment, physician supervision throughout, structured observation, documented response procedures, continuity of records, and follow-up that catches problems before they escalate. The right question for any clinic isn't "have you ever had a problem?" It's "what's the system if you do?"
Take a free two-minute self-assessment. Ten short questions about your situation, goals, and timing, and you get a result matched to where you actually are. Educational only, and it helps our team understand whether regenerative care is a reasonable fit for you.
Free Self-Assessment → Free case review, no cost, no obligation.